Local Institution

Tampa, Florida 33613

0 studies enrolling now · 29 studies all time

What they study most

AIDS, Acute Coronary Syndromes, Advanced Cancer, Bipolar Disorder, Blast Crisis, Cancer of the Stomach, Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia, Congestive Heart Failure, Dermatitis, Atopic, Diabetes Mellitus, Type 2, Gastric Cancer

Studies at this site

• A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis — Completed
• A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma — Completed
• A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis — Completed
• Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants — Withdrawn before enrolling
• A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart — Completed
• An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma — Withdrawn before enrolling
• Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer — Completed
• An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer — Completed
• Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone — Completed
• Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve) — Completed
• Study of Aripiprazole in Patients With Acute Bipolar Mania — Completed
• Aripiprazole Open-Label, Safety and Tolerability Study — Completed
• Aripiprazole in Adolescents With Schizophrenia — Completed
• Aripiprazole in Children and Adolescents With Bipolar I Disorder — Completed
• Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib — Completed
• Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma — Withdrawn before enrolling
• Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past. — Completed
• Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen — Completed
• Rollover Study for Zerit (Stavudine) ER Studies (-096, -099) — Completed
• Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension — Completed
• Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia — Completed
• A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy — Completed
• A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen — Completed
• Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia — Completed
• Atazanavir for HIV Infected Individuals: An Early Access Program — NO_LONGER_AVAILABLE
• Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate — Completed
• Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia — Completed
• Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen — Completed
• A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen — Completed